A Single-center, Single-arm, Open-label, Dose-escalation Clinical Study to Evaluate the Safety and Anti-tumor Efficacy of Second-line Systemic Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer

Zhejiang University1 site in 1 country30 target enrollmentJuly 9, 2024

ConditionsPancreatic Cancer Non-resectable

Interventionschemotherapy sequential CAR-NK cell infusion

Drugschemotherapy sequential CAR-NK cell infusion

Overview

Phase: Early Phase 1
Intervention: chemotherapy sequential CAR-NK cell infusion
Conditions: Pancreatic Cancer Non-resectable
Sponsor: Zhejiang University
Enrollment: 30
Locations: 1
Primary Endpoint: Maximum tolerated dose
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a single-center, single-arm, open-label, dose-escalation clinical study to evaluate the safety and anti-tumor efficacy of second-line systemic chemotherapy sequential NKG2D CAR-NK cell therapy for pancreatic cancer

Registry

clinicaltrials.gov

Start Date

July 9, 2024

End Date

July 31, 2026

Last Updated

last year

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Zhejiang University

Responsible Party

Principal Investigator

TingBo Liang

Professor

Zhejiang University

Eligibility Criteria

Inclusion Criteria

•Age between 18\~75 years old (including boundary value), both male and female.
•Histologically or cytologically confirmed pancreatic ductal adenocarcinoma or IPMN carcinosis with at least first-line systemic therapy failure.
•Zubrod-ECOG-WHO score (see Annex 2) on a scale of 0-
•Life expectancy of at least 3 months at screening, as judged by the investigator.
•At least one stably evaluable target lesion according to RECIST1.1 criteria.
•Subject has adequate organ and bone marrow function. Laboratory screening results should be within the stable range described below, with no ongoing supportive care (\"yellowing\" therapy such as PTCD, ENBD, or bile duct stenting is allowed when pancreatic cancer invades the common bile duct).
•Remission of all toxicities due to prior antineoplastic therapy to Grade 0\~1 (according to NCI CTCAE version 5.0) or to acceptable levels for inclusion/exclusion criteria.
•Childbearing status: not pregnant, and if of childbearing potential, willing to use effective contraception from the time of signing the informed consent form to 6 months after the last cell infusion (females of childbearing potential include premenopausal females and females within 2 years of postmenopause).
•Subjects must sign and date written informed consent.
•Subjects must be voluntary and able to comply with predetermined treatment regimens, laboratory tests, follow-up, and other study requirements.

Exclusion Criteria

•Pregnant and lactating females.
•Positive serology for HIV, Treponema pallidum or HCV (those who are HCV antibody positive but HCV-RNA negative, stable syphilis and inactive patients can be included).
•Any active infection, including but not limited to active tuberculosis, HBV infection (including HBsAg positive, or HBcAb positive with HBV DNA above the lower limit of laboratory testing), Epstein-Barr virus (EBV) DNA positive, cytomegalovirus (CMV) DNA positive or novel coronavirus (new coronavirus) nucleic acid positive, and other bacterial, viral, or fungal infections requiring drug treatment;
•History of malignancy within 5 years, with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix.
•Any other health condition that, in the judgment of the investigator, would preclude participation in the study.